NCT05727267View on ClinicalTrials.gov

A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2026

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

HEPLISAV B; TherVacB

Administration of the described combinations via the intramuscular route

BIOLOGICAL

TherVacB

Administration of the described combinations via the intramuscular route

Trial Locations (2)

20359

NOT_YET_RECRUITING

Bernhard Nocht Centre for Clinical Trials (BNCCT), Hamburg

80802

RECRUITING

Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Munich

Sponsors
All Listed Sponsors
collaborator

German Center for Infection Research

OTHER

collaborator

Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf

UNKNOWN

collaborator

Helmholtz Zentrum München

INDUSTRY

collaborator

The Fraunhofer-Gesellschaft

OTHER

collaborator

Institute of Virology Helmholtz Zentrum München (HMGU)

UNKNOWN

collaborator

LMU Klinikum

OTHER

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT05727267 - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate | Biotech Hunter | Biotech Hunter